Special Issue

Radiomics/Radiogenomics in Cancer

Message from the Guest Editor

Recently, studies in radiomics raised hopes of the possibility to improve the reproducibility of imagingbased diagnosis as well as to facilitate discoveries of novel biomarkers that can be used to improve early detection and characterization of neoplastic disease. Physicians do not rely exclusively on a single input for their clinical assessment of complex tasks, including prediction of treatment response and stratification of patients into groups with different prognosis. They integrate heterogeneous information to reach a clinical decision. In the same way, more integrative approaches to model tumor biology have been proposed. This combinatory approach can be applied using two different strategies, either to identify associations between different data sources or to evaluate their complementarity to improve diagnostic performance further. In particular, strong interest exists in combining radiomics and genomics in various types of cancers, including but not limited to the brain, breast, lung, and prostate.

Guest Editor

Dr. Nikolaos Papanikolaou

- 1. Computational Clinical Imaging Group, Champalimaud Foundation, Lisbon, Portugal
- 2. Computational Medicine Lab, Institute of Computer Science, FORTH, Crete, Greece
- 3. Karolinska Institute, Stockholm, Sweden

Deadline for manuscript submissions

closed (30 September 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/55137

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

